Viewing Study NCT02789332

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:44 PM
Ignite Modification Date: 2026-04-19 @ 5:05 AM
Study NCT ID: NCT02789332
Status: COMPLETED
Last Update Posted: 2020-03-17
First Post: 2016-05-23
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Sponsor: GBG Forschungs GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Triple Negative Breast Neoplasms View
None HRpos Breast Neoplasms View
None BRCA 1 /2 and / or HRD View
Keywords:

Keywords

Keyword Brief Keyword Text View
None carboplatin View
None olaparib View
None pCR View
None neoadjuvant View
None triple-negative View
None hormonreceptor-positive View
None BRCA1/2 View
None HRD, homologous recominant deficient View
None breast cancer View
None genetic testing (somatic and germline mutations) View